TrialsgrambetaRCTs are beautiful

COPD

11 trials
  • 2022RETHINCPreserved spirometryIn 535 symptomatic tobacco-exposed adults with preserved spirometry, indacaterol-glycopyrronium for 12 weeks did not improve respiratory symptoms (SGRQ ≥4-point response) compared with placebo.
  • 2020ETHOSSingle-inhaler tripleIn 8,509 patients with moderate-to-very-severe COPD, budesonide/glycopyrrolate/formoterol (BGF 320/18/9.6 µg) reduced annual exacerbations compared with LAMA/LABA (GFF) and LABA/ICS (BFF).
  • 2019BLOCK-COPDβ-blocker safetyIn 532 patients with moderate-to-severe COPD without cardiac indication for β-blockade, metoprolol succinate did not reduce time to first exacerbation and increased severe exacerbations compared with placebo.
  • 2018IMPACTSingle-inhaler tripleIn 10,355 symptomatic COPD patients with ≥1 exacerbation per year, single-inhaler triple therapy (fluticasone furoate / umeclidinium / vilanterol) reduced moderate-or-severe exacerbations and mortality compared with the LAMA/LABA or LABA/ICS components.
  • 2016FLAMELABA/LAMA vs ICS/LABAIn 3,362 COPD patients with ≥1 exacerbation in the prior year, indacaterol-glycopyrronium (LABA/LAMA) reduced annual exacerbation rate compared with salmeterol-fluticasone (LABA/ICS).
  • 2016SUMMIT (COPD)ICS/LABA, CV riskIn 16,485 patients with moderate COPD and CVD or high CV risk, fluticasone furoate-vilanterol did not reduce all-cause mortality compared with placebo.
  • 2014WISDOMICS withdrawalIn 2,485 patients with severe COPD on triple therapy, stepwise withdrawal of inhaled corticosteroids was non-inferior for time to moderate-or-severe exacerbation compared with continued ICS.
  • 2013REDUCESteroid durationIn 314 patients with a COPD exacerbation, 5 days of 40 mg prednisone was non-inferior for re-exacerbation at 180 days compared with 14 days of treatment.
  • 2008UPLIFTLAMAIn 5,993 patients with COPD and FEV1 ≤70%, tiotropium 18 µg daily for four years did not slow rate of FEV1 decline compared with placebo.
  • 2007TORCHICS/LABAIn 6,112 patients with moderate-to-severe COPD, salmeterol-fluticasone reduced 3-year all-cause mortality only borderline-significantly compared with placebo.
  • 1995Brochard NIVNIVIn 85 patients with acute hypercapnic respiratory failure from COPD, face-mask non-invasive ventilation reduced intubation and in-hospital mortality compared with standard therapy.